Ovid Therapeutics (OVID) News Today → DON’T buy gold until you read this (From Sasco Gold LLC) (Ad) Free OVID Stock Alerts $3.10 +0.14 (+4.73%) (As of 06/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1, 2024 | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 28, 2024 | investorplace.com3 Sorry Penny Stocks to Sell in May While You Still CanMay 20, 2024 | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350May 20, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024May 16, 2024 | marketbeat.comOvid Therapeutics' (OVID) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Ovid Therapeutics in a research report on Thursday.May 16, 2024 | marketbeat.comFY2024 EPS Estimates for Ovid Therapeutics Inc. Decreased by Wedbush (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Investment analysts at Wedbush dropped their FY2024 EPS estimates for shares of Ovid Therapeutics in a report released on Tuesday, May 14th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.74) for theMay 16, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Financials and Promising Drug PipelineMay 15, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) to Post Q1 2025 Earnings of ($0.24) Per Share, Wedbush ForecastsOvid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a note issued to investors on Tuesday, May 14th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.24) per share for the quarteMay 14, 2024 | investorplace.comOVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates and First Quarter 2024 Financial ResultsMay 13, 2024 | globenewswire.comOvid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 7, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Ovid TherapeuticsMay 7, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have giveMay 7, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) PT Lowered to $3.50 at CitigroupCitigroup cut their target price on shares of Ovid Therapeutics from $4.00 to $3.50 and set a "neutral" rating on the stock in a research note on Tuesday.May 2, 2024 | marketbeat.comResearch Analysts Offer Predictions for Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at B. Riley issued their Q1 2024 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a research note issued to investors on Monday, April 29th. B. Riley analyst K. Patel expects that the company willMay 1, 2024 | marketbeat.comFFT Wealth Management LLC Invests $1.27 Million in Ovid Therapeutics Inc. (NASDAQ:OVID)FFT Wealth Management LLC acquired a new position in Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 395,774 shares of the company's stock, valued at approximately $1,274,000. FFT Wealth Management LLC owMay 1, 2024 | marketbeat.comHC Wainwright Weighs in on Ovid Therapeutics Inc.'s Q1 2024 Earnings (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Analysts at HC Wainwright issued their Q1 2024 EPS estimates for shares of Ovid Therapeutics in a research report issued on Monday, April 29th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.22) per shareApril 30, 2024 | nasdaq.comHC Wainwright & Co. Initiates Coverage of Ovid Therapeutics (OVID) with Buy RecommendationApril 30, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Now Covered by Analysts at B. RileyB. Riley initiated coverage on shares of Ovid Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $9.00 price target on the stock.April 18, 2024 | finance.yahoo.comWe Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business GrowthApril 13, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Short Interest Down 23.7% in MarchOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 2,800,000 shares, a drop of 23.7% from the March 15th total of 3,670,000 shares. Based on an average daily trading volume, of 205,000 shares, the short-interest ratio is currently 13.7 days. Currently, 4.8% of the shares of the stock are short sold.April 5, 2024 | msn.comOvid Therapeutics gains on bullish view at WedbushApril 5, 2024 | marketbeat.comOvid Therapeutics (NASDAQ:OVID) Coverage Initiated at WedbushWedbush started coverage on Ovid Therapeutics in a report on Friday. They set an "outperform" rating and a $8.00 price objective on the stock.April 4, 2024 | globenewswire.comOvid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | msn.comMarinus Pharmaceuticals Stands Firm in Patent Dispute Over Key Epilepsy TreatmentMarch 29, 2024 | bizjournals.comMarinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twistMarch 22, 2024 | investing.comOvid therapeutics CEO acquires $50k in company stockMarch 22, 2024 | finance.yahoo.comOvid Therapeutics Reaches US$197m Market Cap Benefiting Insider Stock BuyingMarch 21, 2024 | insidertrades.comOvid Therapeutics Inc. (NASDAQ:OVID) CEO Jeremy M. Levin Acquires 18,248 SharesMarch 20, 2024 | marketbeat.comJeremy M. Levin Purchases 18,248 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) StockOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) CEO Jeremy M. Levin purchased 18,248 shares of the stock in a transaction dated Monday, March 18th. The shares were acquired at an average price of $2.76 per share, with a total value of $50,364.48. Following the transaction, the chief executive officer now owns 3,616,715 shares in the company, valued at $9,982,133.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.March 17, 2024 | insidermonkey.com5 Oversold Biotech Stocks To Buy Right NowMarch 13, 2024 | markets.businessinsider.comOvid Therapeutics: Strong Buy Rating on Robust Pipeline and Strategic PartnershipsMarch 13, 2024 | news.yahoo.comOvid gas station, state and local officials dealing with contaminated fuel problemMarch 13, 2024 | msn.comOvid gas station shut down after discovery of water inside pumpsMarch 11, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)March 9, 2024 | finance.yahoo.comOVID Oct 2024 7.500 callMarch 8, 2024 | benzinga.comRecap: Ovid Therapeutics Q4 EarningsMarch 8, 2024 | globenewswire.comOvid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | investing.comOvid Therapeutics Inc (OVID)February 28, 2024 | globenewswire.comOvid Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | news.yahoo.comOvid-Elsie girls win third straight conference titleFebruary 17, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Short Interest UpdateOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 3,340,000 shares, an increase of 8.4% from the January 15th total of 3,080,000 shares. Based on an average daily trading volume, of 142,100 shares, the short-interest ratio is currently 23.5 days. Currently, 5.6% of the shares of the stock are sold short.February 17, 2024 | finance.yahoo.comOVID Mar 2024 5.000 callFebruary 17, 2024 | finance.yahoo.comOVID Apr 2024 5.000 callFebruary 15, 2024 | msn.comTaysha transfers rights to 3 programs, extends cash runway into 2026February 6, 2024 | finance.yahoo.comOvid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 1, 2024 | msn.comCirculatory cholesterol levels are inversely linked to mortality of patients with sepsis and critical illnessJanuary 18, 2024 | finance.yahoo.comOwning 31% shares,hedge funds owners seem interested in Ovid Therapeutics Inc. (NASDAQ:OVID),January 14, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Sees Large Increase in Short InterestOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 2,900,000 shares, a growth of 16.9% from the December 15th total of 2,480,000 shares. Based on an average daily trading volume, of 136,300 shares, the short-interest ratio is presently 21.3 days. Approximately 4.9% of the company's shares are short sold. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Top 5 Tech Stocks to Buy for 2024 (Ad)The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution… Click below for your free report "Top 5 Tech Stocks to Buy in 2024", OVID Media Mentions By Week OVID Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼0.000.74▲Average Medical News Sentiment OVID News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼01▲OVID Articles Average Week Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMUX News ABVX News CNTA News COGT News STOK News OCUL News ETNB News PRTC News ZNTL News EOLS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersA once-in-a-century investment opportunityIt's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more poten...Stansberry Research | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored